Reactive oxygen species, inflammation, and lung diseases.

abstract：BACKGROUND:Enhancing a compound's biological activity is the central task for lead optimization in small molecules drug discovery. However, it is laborious to perform many iterative rounds of compound synthesis and bioactivity tests. To address the issue, it is highly demanding to develop high quality in silico bioacti...

journal_title：Current pharmaceutical design

authors： Ding X,Cui C,Wang D,Zhao J,Zheng M,Luo X,Jiang H,Chen K

更新日期：2020-01-01 00:00:00

abstract：:Sarcopenia is defined as the loss of muscle mass associated with a loss of muscle function, e.g., walking speed. A number of consensus definitions exist for sarcopenia with cut-off points being ethnically specific. A rapid screen test (SARC-F) is available and does not require different ethnic cut-off points. Sarcopen...

journal_title：Current pharmaceutical design

authors： Morley JE

更新日期：2017-11-28 00:00:00

abstract：:It is generally accepted that mitochondrial dysfunction and endoplasmic reticulum (ER) stress are related to insulin resistance and type 2 diabetes. Mitochondria use substrates from lipid and glucose metabolism in order to generate ATP, and when mitochondrial O2 consumption is decreased due to an altered metabolism th...

journal_title：Current pharmaceutical design

authors： Rocha M,Diaz-Morales N,Rovira-Llopis S,Escribano-Lopez I,Bañuls C,Hernandez-Mijares A,Diamanti-Kandarakis E,Victor VM

更新日期：2016-01-01 00:00:00

abstract：:Lactoferrin (Lf) is a conserved cationic non-heme glycoprotein that is part of the innate immune defense system of mammals. Lf is present in colostrum, milk and mucosal sites, and it is also produced by polymorphonuclear neutrophils and secreted at infection sites. Lf and Lf N-terminus peptide-derivatives named lactof...

journal_title：Current pharmaceutical design

authors： Drago-Serrano ME,Campos-Rodriguez R,Carrero JC,de la Garza M

更新日期：2018-01-01 00:00:00

abstract：:Multiple molecular, cellular, structural and functional changes occur in the brain during aging. Neural cells may respond to these changes adaptively by employing multiple mechanisms in order to maintain the integrity of nerve cell circuits and to facilitate responses to environmental demands. Otherwise, they may succ...

journal_title：Current pharmaceutical design

authors： Lanni C,Stanga S,Racchi M,Govoni S

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Medical treatments are used either alone or in combination with assisted reproductive techniques for treatment of infertile patients with hypergonadotropic hypogonadism. A wide range of treatment options such as gonadotropins, aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) and the...

journal_title：Current pharmaceutical design

authors： Kalkanli A,Akdere H,Cevik G,Salabas E,Cilesiz NC,Kadioglu A

更新日期：2020-11-01 00:00:00

abstract：:Parkinson's disease (PD) is a common neurodegenerative disorder characterized by cardinal features of tremor, bradykinesia, rigidity and postural instability. In addition to the motor symptoms patients experience cognitive decline eventually resulting in severe disability. Pathologically PD is characterized by neurode...

journal_title：Current pharmaceutical design

authors： Thomas M,Le WD

更新日期：2004-01-01 00:00:00

abstract：:In the last two decades the development of efficient plant-based expression strategies and new concepts for the purification of recombinant proteins prompted the application of plant-derived vaccines for veterinary purposes. The expression of recombinant proteins in plants possesses advantages over conventional eukary...

journal_title：Current pharmaceutical design

authors： Phan HT,Floss DM,Conrad U

更新日期：2013-01-01 00:00:00

abstract：:Atherosclerosis is a multifactorial and long-lasting process in humans. Therefore, animal models where more rapid changes occur can be useful for the study of this process. Among such models are the apolipoprotein (apo) E knock out mice. Apo E deficient mice show impaired clearing of plasma lipoproteins and they devel...

journal_title：Current pharmaceutical design

authors： Kolovou G,Anagnostopoulou K,Mikhailidis DP,Cokkinos DV

更新日期：2008-01-01 00:00:00

abstract：:Gene therapy, currently, represents one of the new therapies that have emerged for the treatment of different diseases. Between the different approaches that can be chosen concerning this therapy, gene delivery with non-viral systems has focused the attention during the past decades, because of the reduced toxicity co...

journal_title：Current pharmaceutical design

authors： Urbiola K,Blanco-Fernandez L,de Ilarduya CT

更新日期：2015-01-01 00:00:00

abstract：:Marine fungi with their successful pharmacological effects were considered to be the treasure of ocean medicines concerning the striking ability of their secondary metabolites. Literature over literature has been published on fungi derived bioactive molecules to probe its therapeutic potential. Marine fungi have an im...

journal_title：Current pharmaceutical design

authors： Shams Ul Hassan S,Ishaq M,Zhang WD,Jin HZ

更新日期：2020-07-28 00:00:00

abstract：BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is a global epidemic involving 20-40% of the general population. NAFLD is rapidly becoming the leading cause of hepatocellular carcinoma (HCC) worldwide. Knowledge about NAFLD-HCC peculiar features is needed to understand this emerging disease better. OBJECTIVE:To r...

journal_title：Current pharmaceutical design

authors： Tovoli F,Ferri S,Piscaglia F

更新日期：2020-01-01 00:00:00

abstract：:A wide range of peptides and polypeptides can be appended to either the N- or C-terminus of G protein-coupled receptors without disrupting substantially ligand binding and signal transduction. Following fusion of fluorescent proteins, reporter gene constructs or G protein alpha subunits to the C-terminal tail of a rec...

journal_title：Current pharmaceutical design

authors： Milligan G,Feng GJ,Ward RJ,Sartania N,Ramsay D,McLean AJ,Carrillo JJ

更新日期：2004-01-01 00:00:00

abstract：:The antimicrobial agents used in the treatment of mycobacterial infections have remained largely unchanged for several decades. Primary treatment of tuberculosis relies on four drugs, isoniazid, a rifamycin, pyrazinamide, and ethambutol (or streptomycin), and generally results in >95% cure in uncomplicated tuberculosi...

journal_title：Current pharmaceutical design

authors： Jacobs MR

更新日期：2004-01-01 00:00:00

abstract：:Gene therapy may be capable of treating a variety of diseases, a prerequisite of which is the successful delivery of polynucleic acids (e.g., DNA, RNA) to a patient's cells. Delivery can be achieved technologically (e.g., using electroporation), using viruses (natural gene delivery vectors) or non-viral vectors (e.g.,...

journal_title：Current pharmaceutical design

authors： Clancy KFA,Hardy JG

更新日期：2017-01-01 00:00:00

abstract：:Ischaemic stroke of the brain accounts for about one third of all deaths in industrialized countries. Many of the patients who survive are severily impaired. Thus, there is an enormous need for pharmacotherapy for the treatment of ischaemic stroke. Why is such a treatment not available yet? Are the pathophysiological ...

journal_title：Current pharmaceutical design

authors： Weiser T

更新日期：2002-01-01 00:00:00

abstract：:The diatomic molecule of oxygen contains two uncoupled electrons and can therefore undergo reduction, yielding several different oxygen metabolites, which are collectively called Reactive Oxygen Species or ROS. They are invariably produced in aerobic environments through a variety of mechanisms, which include electron...

journal_title：Current pharmaceutical design

authors： Bergamini CM,Gambetti S,Dondi A,Cervellati C

更新日期：2004-01-01 00:00:00

abstract：:Protein stability of hypoxia-inducible factor (HIF)alpha subunits is regulated by the oxygen-sensing prolyl-4-hydroxylase domain (PHD) enzymes. Under oxygen-limited conditions, HIFalpha subunits are stabilized and form active HIF transcription factors that induce a large number of genes involved in adaptation to hypox...

journal_title：Current pharmaceutical design

authors： Wenger RH,Camenisch G,Stiehl DP,Katschinski DM

更新日期：2009-01-01 00:00:00

abstract：:The comorbid prevalence of major depressive disorder (MDD) with obesity and type II diabetes mellitus reflects the existence of a subset of individuals with a complex common pathophysiology and overlapping risk factors. Such comorbid disease presentations imply a number of difficulties, including: decreased treatment ...

journal_title：Current pharmaceutical design

authors： Slyepchenko A,Maes M,Machado-Vieira R,Anderson G,Solmi M,Sanz Y,Berk M,Köhler CA,Carvalho AF

更新日期：2016-01-01 00:00:00

abstract：:Cell therapy has been proposed to treat patients with end-stage heart failure. However, it has been suggested that the significant mechanical forces in an often ischaemic, inflamed, biochemically hostile environment may cause poor cell survival and retention. It is hypothesised that tissue engineering techniques could...

journal_title：Current pharmaceutical design

authors： Rao C,Barratt H,Prodromakis T,Terracciano CM

更新日期：2014-01-01 00:00:00

abstract：:Alzheimer's disease (AD) is a heterogeneous and progressive neurodegenerative disease which in Western society mainly accounts for clinical dementia. Inflammation plays a key role in AD and dissecting the genetics of inflammation may provide an answer to the possible treatment. Hence, the better understanding of diffe...

journal_title：Current pharmaceutical design

authors： Balistreri CR,Grimaldi MP,Chiappelli M,Licastro F,Castiglia L,Listì F,Vasto S,Lio D,Caruso C,Candore G

更新日期：2008-01-01 00:00:00

abstract：:Pituitary adenylate cyclase-activating polypeptide (PACAP) is a novel member of the secretin/glucagon/vasoactive intestinal peptide (VIP) superfamily. In vertebrates, including avians, it occurs in two forms: PACAP(38) and PACAP(27). PACAP structure is well conserved during evolution, being identical in mammals, and s...

journal_title：Current pharmaceutical design

authors： Nowak JZ,Zawilska JB

更新日期：2003-01-01 00:00:00

abstract：:Syncytin-1 is a protein coded by a human endogenous retrovirus (HERV) gene of the HERV-W family (HERVWE1). Syncytin- 1 mediates formation of syncytiotrophoblasts through fusion of cytotrophoblasts, a hallmark of terminal differentiation of placental trophoblast linage. Syncytin-1 also possesses nonfusogenic functions ...

journal_title：Current pharmaceutical design

authors： Zhuang XW,Li J,Brost BC,Xia XY,Chen HB,Wang CX,Jiang SW

更新日期：2014-01-01 00:00:00

abstract：:Opioids remain the standard of care in the provision of analgesia in the patient undergoing cancer surgery preoperatively. The effects of opioids on tumor growth and metastasis have been discussed for many years. In recent years their use as part of the perioperative pain management bundle in the patients undergoing c...

journal_title：Current pharmaceutical design

authors： Sekandarzad MW,Doornebal C,Hollmann MW

更新日期：2019-01-01 00:00:00

abstract：:Reduced levels of high-density lipoprotein cholesterol (HDL) are associated with a substantially increased risk of coronary disease and cardiovascular events. Furthermore, numerous studies have suggested that HDL may exert several potentially important antiatherosclerotic and endothelial-protective effects. In particu...

journal_title：Current pharmaceutical design

authors： Besler C,Heinrich K,Riwanto M,Lüscher TF,Landmesser U

更新日期：2010-05-01 00:00:00

abstract：:Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular, endocrinological and psychogenic components described. However, about 50-85% of ED population report the presence of one or more comorbidities i.e. hypertension, diabetes, cardiovascular disease, dyslipidemia which all impair endothel...

journal_title：Current pharmaceutical design

authors： Aversa A,Bruzziches R,Pili M,Spera G

更新日期：2006-01-01 00:00:00

abstract：:In order to productively infect a host, viruses must enter the cell and force host cell replication mechanisms to produce new infectious virus particles. The success of this process unfortunately results in disease progression and, in the case of infection with many viral species, may cause mortality. The discoveries ...

journal_title：Current pharmaceutical design

authors： Skoreński M,Sieńczyk M

更新日期：2013-01-01 00:00:00

abstract：:Inhibition of carbonic anhydrase (CA, EC 4.2.1.1) isoforms present in the eyes (CA I, II, IV and XII), with sulfonamides such as acetazolamide, methazolamide, ethoxzolamide and dichlorophenamide, is still widely used for the systemic treatment of glaucoma. The mechanism of action of these drugs consists in inhibition ...

journal_title：Current pharmaceutical design

authors： Mincione F,Scozzafava A,Supuran CT

更新日期：2008-01-01 00:00:00

abstract：:Fever of Unknown Origin, or FUO, is a challenging condition for patients and clinicians. In up to 50% of cases, no diagnosis is established. Patient workup begins with comprehensive history, physical examination and laboratory tests. Radionuclide imaging has been a second-line procedure. Gallium-67 citrate, which accu...

journal_title：Current pharmaceutical design

authors： Palestro CJ,Love C

更新日期：2018-01-01 00:00:00

abstract：:Humans have always lived with tubercle bacilli. Host susceptibility both inherited and acquired determines whether an individual infected with Mycobacterium tuberculosis will eventually fall ill and develop tuberculosis (TB). After infection with M. tuberculosis, a latent TB infection may ensue reflected by immune r...

journal_title：Current pharmaceutical design

authors： van Altena R,Duggirala S,Gröschel MI,van der Werf TS

更新日期：2011-01-01 00:00:00